Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain
- PMID: 23843566
- DOI: 10.2967/jnumed.112.118679
Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain
Abstract
Phosphodiesterase 10A (PDE10A) plays a central role in striatal signaling and is implicated in several neuropsychiatric disorders, such as movement disorders and schizophrenia. We performed initial brain kinetic modeling of the novel PDE10A tracer (18)F-JNJ-42259152 (2-[[4-[1-(2-(18)F-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-3,5-dimethyl-pyridine) and studied test-retest reproducibility in healthy volunteers.
Methods: Twelve healthy volunteers (5 men, 7 women; age range, 42-77 y) were scanned dynamically up to 135 min after bolus injection of 172.5 ± 10.3 MBq of (18)F-JNJ42259152. Four volunteers (2 men, 2 women) underwent retest scanning, with a mean interscan interval of 37 d. Input functions and tracer parent fractions were determined using arterial sampling and high-performance liquid chromatography analysis. Volumes of interest for the putamen, caudate nucleus, ventral striatum, substantia nigra, thalamus, frontal cortex, and cerebellum were delineated using individual volumetric T1 MR imaging scans. One-tissue (1T) and 2-tissue (2T) models were evaluated to calculate total distribution volume (VT). Simplified models were also tested to calculate binding potential (BPND), including the simplified reference tissue model (SRTM) and multilinear reference tissue model, using the frontal cortex as the optimal reference tissue. The stability of VT and BPND was assessed down to a 60-min scan time.
Results: The average intact tracer half-life in blood was 90 min. The 2T model VT values for the putamen, caudate nucleus, ventral striatum, substantia nigra, thalamus, frontal cortex, and cerebellum were 1.54 ± 0.37, 0.90 ± 0.24, 0.64 ± 0.18, 0.42 ± 0.09, 0.35 ± 0.09, 0.30 ± 0.07, and 0.36 ± 0.12, respectively. The 1T model provided significantly lower VT values, which were well correlated to the 2T VT. SRTM BPND values referenced to the frontal cortex were 3.45 ± 0.43, 1.78 ± 0.35, 1.10 ± 0.31, and 0.44 ± 0.09 for the respective target regions putamen, caudate nucleus, ventral striatum, and substantia nigra, with similar values for the multilinear reference tissue model. Good correlations were found for the target regions putamen, caudate nucleus, ventral striatum, and substantia nigra between the 2T-compartment model BPND and the SRTM BPND (r = 0.57, 0.82, 0.70, and 0.64, respectively). SRTM BPND using a 90- and 60-min acquisition interval showed low bias. Test-retest variability was 5%-19% for 2T VT and 5%-12% for BPND SRTM.
Conclusion: Kinetic modeling of (18)F-JNJ-42259152 shows that PDE10A activity can be reliably quantified and simplified using a reference tissue model with the frontal cortex as reference and a 60-min acquisition period.
Keywords: 18F; PDE10A; PET; phosphodiesterase; radioligand.
Similar articles
-
Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A.Neuroimage. 2013 Nov 15;82:13-22. doi: 10.1016/j.neuroimage.2013.04.123. Epub 2013 May 9. Neuroimage. 2013. PMID: 23664955
-
In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654.J Nucl Med. 2014 Aug;55(8):1297-304. doi: 10.2967/jnumed.113.122895. Epub 2014 Jun 4. J Nucl Med. 2014. PMID: 24898025
-
Preclinical Evaluation and Quantification of 18F-Fluoroethyl and 18F-Fluoropropyl Analogs of SCH442416 as Radioligands for PET Imaging of the Adenosine A2A Receptor in Rat Brain.J Nucl Med. 2017 Mar;58(3):466-472. doi: 10.2967/jnumed.116.178103. Epub 2016 Oct 27. J Nucl Med. 2017. PMID: 27789720
-
2-{4-[-Pyridin-4-yl-1-(2-[18F]fluoro-ethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline.2010 Dec 20 [updated 2011 Mar 2]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Dec 20 [updated 2011 Mar 2]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21391339 Free Books & Documents. Review.
-
PET Radioligands for imaging of the PDE10A in human: current status.Neurosci Lett. 2019 Jan 19;691:11-17. doi: 10.1016/j.neulet.2018.08.006. Epub 2018 Aug 10. Neurosci Lett. 2019. PMID: 30099081 Review.
Cited by
-
Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis.Synapse. 2015 Feb;69(2):86-95. doi: 10.1002/syn.21792. Epub 2014 Dec 11. Synapse. 2015. PMID: 25450608 Free PMC article.
-
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):451-489. doi: 10.1007/s00259-019-04488-0. Epub 2019 Sep 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 31541283 Free PMC article. Review.
-
Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats.Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):492-502. doi: 10.1007/s00259-021-05448-3. Epub 2021 Jun 17. Eur J Nucl Med Mol Imaging. 2022. PMID: 34142214
-
Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.J Med Chem. 2015 Nov 12;58(21):8584-600. doi: 10.1021/acs.jmedchem.5b01205. Epub 2015 Oct 15. J Med Chem. 2015. PMID: 26430878 Free PMC article.
-
Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue.Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):396-406. doi: 10.1007/s00259-018-4119-8. Epub 2018 Aug 18. Eur J Nucl Med Mol Imaging. 2019. PMID: 30121895
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources